# A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma

> **NCT00920556** · PHASE2 · TERMINATED · sponsor: **Sirtris, a GSK Company** · enrollment: 24 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** 5.0g SRT501
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00920556
- **Lead sponsor:** Sirtris, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03-30
- **Primary completion:** 2010-11-04
- **Final completion:** 2010-11-04
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Study terminated.24 subjects enrolled;provided adequate data for decision making.
- **Last updated:** 2019-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920556, "A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00920556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*